Gwan Gyu Song1, Young Ho Lee. 1. Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine , Seoul , Korea.
Abstract
OBJECTIVE: The aim of this study was to determine whether the functional chemokine receptor 5 delta32 (CCR5-Δ32) polymorphism is associated with multiple sclerosis (MS) susceptibility. METHODS: Meta-analysis was conducted to determine the association between the CCR5-Δ32 polymorphism and overall incidence of MS as well frequency of relapsing-remitting (RR), primary progressive (PP), and secondary progressive (SP) MS subtypes. RESULTS: In total, 3869 subjects from eight studies (MS 1666, controls 2203) were considered for meta-analysis. Meta-analysis showed no association between MS and the CCR5-Δ32 allele polymorphism (OR=1.102, 95% CI=0.830-1.462, p=0.502) with a mean frequency of 11.3% in MS patients and 10.4% in controls. Stratification by ethnicity indicated no association between the CCR5-Δ32 allele and MS in Europeans (OR=0.958, 95% CI=0.811-1.132, p=0.618). Meta-analysis by the disease subtype showed no association between RR-MS and the CCR5-Δ32 allele (OR=1.234, 95% CI=0.908-1.677, p=0.178). In addition, no association was found between the CCR5-Δ32 polymorphism and PP or SP-MS. CONCLUSIONS: Meta-analysis of 3869 subjects indicates a lack of association between the CCR5-Δ32 polymorphism and MS risk in Europeans.
OBJECTIVE: The aim of this study was to determine whether the functional chemokine receptor 5 delta32 (CCR5-Δ32) polymorphism is associated with multiple sclerosis (MS) susceptibility. METHODS: Meta-analysis was conducted to determine the association between the CCR5-Δ32 polymorphism and overall incidence of MS as well frequency of relapsing-remitting (RR), primary progressive (PP), and secondary progressive (SP) MS subtypes. RESULTS: In total, 3869 subjects from eight studies (MS 1666, controls 2203) were considered for meta-analysis. Meta-analysis showed no association between MS and the CCR5-Δ32 allele polymorphism (OR=1.102, 95% CI=0.830-1.462, p=0.502) with a mean frequency of 11.3% in MS patients and 10.4% in controls. Stratification by ethnicity indicated no association between the CCR5-Δ32 allele and MS in Europeans (OR=0.958, 95% CI=0.811-1.132, p=0.618). Meta-analysis by the disease subtype showed no association between RR-MS and the CCR5-Δ32 allele (OR=1.234, 95% CI=0.908-1.677, p=0.178). In addition, no association was found between the CCR5-Δ32 polymorphism and PP or SP-MS. CONCLUSIONS: Meta-analysis of 3869 subjects indicates a lack of association between the CCR5-Δ32 polymorphism and MS risk in Europeans.